Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity

Indian J Ophthalmol. 2007 Jul-Aug;55(4):319; author reply 320. doi: 10.4103/0301-4738.33057.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Humans
  • Infant, Newborn
  • Injections
  • Retinopathy of Prematurity / diagnosis
  • Retinopathy of Prematurity / drug therapy*
  • Severity of Illness Index
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab